Cancer tailored next generation cellular therapies

Informazioni relative al progetto

CATACLIS

ID dell’accordo di sovvenzione: 101124203

DOI

10.3030/101124203

Data della firma CE 30 Aprile 2024

Data di avvio 1 Ottobre 2024

Data di completamento 30 Settembre 2029

Finanziato da

• European Research Council (ERC)

Costo totale

€ 2 000 000,00

Contributo UE

€ 2 000 000,00

Coordinato da

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Pubblicazioni

Peer reviewed articles (10)

Serial Killing Assay Using Longitudinal Impedance-Based Tumor Cell Viability Measurement - A Useful Method to Assess T Cell Performance

Autori: Tengis Tschaidse, Marcel P. Trefny, Emanuele Carlini, David Andreu-Sanz, Stefanos Michaelides, Ngoc Thien Thu Nguyen, Sebastian Kobold
Pubblicato in: Journal of Visualized Experiments, 2026, ISSN 1940-087X
Editore: MyJove Corporation
DOI: 10.3791/69623

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

Autori: Adrian Gottschlich, Ruth Grünmeier, Gordon Victor Hoffmann, Sayantan Nandi, Vladyslav Kavaka, Philipp Jie Müller, Jakob Jobst, Arman Oner, Rainer Kaiser, Jan Gärtig, Ignazio Piseddu, Stephanie Frenz-Wiessner, Savannah D. Fairley, Heiko Schulz, Veronika Igl, Thomas Alexander Janert, Lea Di Fina, Maité Mulkers, Moritz Thomas, Daria Briukhovetska, Donjetë Simnica, Emanuele Carlini, Christina Angeliki Tsiverioti, Marcel P. Trefny, Theo Lorenzini, Florian Märkl, Pedro Mesquita, Ruben Brabenec, Thaddäus Strzalkowski, Sophia Stock, Stefanos Michaelides, Johannes Hellmuth, Martin Thelen, Sarah Reinke, Wolfram Klapper, Pascal Francois Gelebart, Leo Nicolai, Carsten Marr, Eduardo Beltrán, Remco T. A. Megens, Christoph Klein, Fanny Baran-Marszak, Andreas Rosenwald, Michael von Bergwelt-Baildon, Paul J. Bröckelmann, Stefan Endres, Sebastian Kobold
Pubblicato in: Blood, Numero 145, 2025, ISSN 0006-4971
Editore: American Society of Hematology
DOI: 10.1182/BLOOD.2023022197

How CAR T cells can be shielded from prostaglandin E2 signaling to enhance their therapeutic activity

Autori: Janina Dörr, David Andreu-Sanz, Sebastian Kobold
Pubblicato in: Molecular Therapy Oncology, Numero 34, 2026, ISSN 2950-3299
Editore: Elsevier BV
DOI: 10.1016/J.OMTON.2026.201204

Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors

Autori: Anne Holtermann, Mila Gislon, Martin Angele, Marion Subklewe, Michael von Bergwelt-Baildon, Kirsten Lauber, Sebastian Kobold
Pubblicato in: BioDrugs, Numero 38, 2024, ISSN 1173-8804
Editore: Springer Science and Business Media LLC
DOI: 10.1007/S40259-024-00669-Y

Tumor microenvironment evolution in lung cancer: Spatio-temporal dynamics and clinical implications

Autori: Selma Dizdarević, Oleg Timofeev, Daniel Kazdal, Soni Savai Pullamsetti, Rocio Sotillo, Sonja Loges, Sebastian Kobold, Albrecht Stenzinger, Thorsten Stiewe, Rajkumar Savai
Pubblicato in: Seminars in Cancer Biology, Numero 123-124, 2026, ISSN 1044-579X
Editore: Elsevier BV
DOI: 10.1016/J.SEMCANCER.2026.04.003

Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours

Autori: Janina Dörr, Lisa Gregor, Sebastian B. Lacher, Arman Oner, Yi Sun, Ignazio Piseddu, Luisa Fertig, Sebastijan Spajic, Stefanie Lesch, Stefanos Michaelides, Matthias Seifert, Adrian Gottschlich, Natasha Samson, Lina Majed, Daria Briukhovetska, Donjetë Simnica, Viktoria Hartmann, Kathrin Gabriel, Sonia Cohen, Genevieve M. Boland, David Andreu-Sanz, Emanuele Carlini, Sophia Stock, Anne Holtermann, Philipp Jie Müller, Thaddäus Strzalkowski, Marcel P. Trefny, Stefan Endres, Russell W. Jenkins, Jan P. Böttcher, Sebastian Kobold
Pubblicato in: Nature Biomedical Engineering, Numero 10, 2026, ISSN 2157-846X
Editore: Springer Science and Business Media LLC
DOI: 10.1038/S41551-025-01610-6

Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy

Autori: Kathrin Gabriel, Sebastian Kobold
Pubblicato in: Signal Transduction and Targeted Therapy, Numero 10, 2025, ISSN 2059-3635
Editore: Springer Science and Business Media LLC
DOI: 10.1038/S41392-025-02324-6

CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases

Autori: Adrian-Bogdan Tigu, Madalina Nistor, Diana Gulei, Catalin-Sorin Constantinescu, David Kegyes, Diana Cenariu, Ximena Muresan, Raluca Munteanu, Richard Feder, Ciprian Jitaru, Anamaria Bancos, Maria Santa, Radu Tomai, Marc Damian, Andrei Ivancuta, Ioana Rus, Anca Bojan, Mihnea Zdrenghea, Anca-Dana Buzoianu, Alina Tanase, Hermann Einsele, Sebastian Kobold, Ciprian Tomuleasa
Pubblicato in: Blood Reviews, Numero 75, 2026, ISSN 0268-960X
Editore: Elsevier BV
DOI: 10.1016/J.BLRE.2025.101354

The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity

Autori: Ngoc Thien Thu Nguyen, Rasmus Müller, Daria Briukhovetska, Justus Weber, Judith Feucht, Annette Künkele, Michael Hudecek, Sebastian Kobold
Pubblicato in: Cancers, Numero 16, 2025, ISSN 2072-6694
Editore: MDPI AG
DOI: 10.3390/CANCERS16142608

Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis

Autori: David Andreu-Sanz, Lisa Gregor, Emanuele Carlini, Daniele Scarcella, Carsten Marr, Sebastian Kobold
Pubblicato in: Journal for ImmunoTherapy of Cancer, Numero 13, 2026, ISSN 2051-1426
Editore: BMJ
DOI: 10.1136/JITC-2025-011698